Potent Targeting of the STAT3 Protein in Brain Cancer Stem Cells: A Promising Route for Treating Glioblastoma


1Department of Chemical and Physical Sciences, University of Toronto at Mississauga, Mississauga, ON L5L 1C6, Canada
2Hotchkiss Brain Institute and Department of Cell Biology and Anatomy, University of Calgary, Calgary, AB T2N 1N4, Canada
3Department of Chemistry, University of Toronto at Scarborough, Toronto, ON M1C 1A4, Canada
4Cell Biology Program and James Burrell Laboratories at the Hospital for Sick Children, Toronto, ON M5G 1X8, Canada
5Drug Discovery Program, Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada

Supporting Information

ABSTRACT: The STAT3 gene is abnormally active in glioblastoma (GBM) and is a critically important mediator of tumor growth and therapeutic resistance in GBM. Thus, for poorly treated brain cancers such as gliomas, astrocytomas, and glioblastomas, which harbor constitutively activated STAT3, a STAT3-targeting therapeutic will be of significant importance. Herein, we report a most potent, small molecule, nonphosphorylated STAT3 inhibitor, 31 (SH-4-54) that strongly binds to STAT3 protein (K_D = 300 nM). Inhibitor 31 potently kills glioblastoma brain cancer stem cells (BTSCs) and effectively suppresses STAT3 phosphorylation and its downstream transcriptional targets at low nM concentrations. Moreover, in vivo, 31 exhibited blood-brain barrier permeability, potently controlled glioma tumor growth, and inhibited pSTAT3 in vivo. This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.

KEYWORDS: STAT3, brain cancer stem cells, glioblastoma, small-molecule inhibitor, protein-protein interactions, anticancer drug
pSTAT3 homodimers are mediated through reciprocal STAT3 Src Homology 2 (SH2) domain-pY705 STAT3 interactions. pSTAT3:pSTAT3 homodimers translocate to the nucleus and bind DNA, promoting STAT3 target gene transcription.8 Targeting STAT3 has been achieved with dominant negative constructs, oligonucleotides,9 or, most commonly, phospho-peptidic agents that mimic the native pY705 containing binding sequence.10−13 or non-native STAT3-binding sequences.14,15 Unfortunately, these inhibitors, possessing pTyr-like groups, are poorly cell permeable and rapidly metabolized in vivo, which has limited their use in the clinic. To circumvent these problems, our group has developed novel small molecule STAT3 inhibitors not containing a phosphate ester.16,17 Using structure-based design, targeting the pTyr-SH2 domain interactions, salicylic acid-based inhibitors have been identified that block STAT3 dimerization and DNA-binding, namely, BP-1-102 (1, Figure 1). BP-1-102 potently suppresses cell proliferation, migration, invasion, and motility. It showed little or no effect on phosphorylation of Jak-1/2, Shc, Src, or Akt. BP-1-102 exhibited potent antitumor effects in in vivo xenograft models of lung and breast cancer. Western blots of tumors showed repression in pSTAT3 in a dose-dependent manner.18−20 We hypothesized that since the STAT3 pathway is a key oncogenic driver in brain tumor stem cells, direct inhibition of STAT3 would provide a targeted route for managing GBM. In this study, we have optimized 1 to be more potent, possess reduced pharmacokinetic labilities and effectively penetrate the blood brain barrier (BBB).

A library of BP-1-102 analogues possessing both prodrugs and potential bioisosteres, as well as salicylic acid mimics, were prepared (Table 1). For improving cell and BBB permeability, prodrugs were synthesized to conceal the carboxylate functionality. In this family, alkyl (21 and 22), acetoxymethyl (AOM) (23), pivaloyloxymethyl (POM) (24), and the acetylated prodrug (19) were prepared to enhance cell penetration. We prepared a nonhydrolyzable phosphonate, 18, as well as its prodrug, 16. In addition, the relative ring positions of the hydroxy- and carboxylate groups of the salicylic acid were inversed (34), the hydroxyl substituent replaced with a fluoride (33) or removed entirely and replaced with a hydrogen atom (31). The fluorinated analogue, 33, was prepared to reduce the charge on the carboxylate and preclude phase II glucoronidation of the phenol. To investigate the salicylic acid’s role in binding STAT3, an N-hydroxyl amino (32), sulfonamide (10−13), sulfonamine (14), tetrazole (29 and 35) and N-hydroxy-oxamic acid (25) derivatives were prepared. As negative controls, we prepared 10, 11, and 30, which possessed hydrophobic naphthyl or benzene groups in place of the salicylic acid.

First, the library was screened for biological activity against GBM BTSC line 30M, derived from a GBM patient. Cell viability following drug treatment was assessed after 72 h using an alamarBlue assay.5,21 IC50 values were derived and compared to BP-1-102. Consistent with previous findings, BP-1-102 exhibited low micromolar activity (Figure 2A). More encouragingly, we identified a number of more potent inhibitors exhibiting low nanomolar IC50 values. Lead compounds were then evaluated against a panel of BTSCs, 25EF, 67EF, 73E, 84EF, and 127EF, which are molecularly heterogeneous human GBM BTSCs (Figure 2B). Compounds displayed IC50 values ranging from 0.1 to 3.8 μM in comparison to BP-1-102, which displayed values above 2−5 μM (BTSC 30M). Compounds SH-05-19 (19), SH-04-54 (31), SH-05-07 (32), and SH-05-23 (33) showed potent activity, with IC50s

---

**Table 1. Focused Library of Inhibitors Consisting of Prodrugs and Bioisosteres of the Salicylic Acid Functionality**

<table>
<thead>
<tr>
<th>#</th>
<th>R1</th>
<th>#</th>
<th>R1</th>
<th>#</th>
<th>R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>NO2</td>
<td>18</td>
<td></td>
<td>28</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>19</td>
<td>CN</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>21</td>
<td>OMe</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>22</td>
<td>OMe</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>23</td>
<td>OMe</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>19</td>
<td></td>
<td>33</td>
<td>F</td>
</tr>
<tr>
<td>18</td>
<td></td>
<td>21</td>
<td></td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td>30</td>
<td></td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td>32</td>
<td></td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>31</td>
<td></td>
<td>19</td>
<td></td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td>33</td>
<td></td>
<td>35</td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 1. In silico docking images of inhibitor 1.**
ranging from 66–1145 nM. However, 31, equipped with a benzoic acid substituent, exhibited higher potency against a larger number of BTSCs and represents a most potent inhibitor of BTSCs (Supporting Information). Inhibitors were next assessed against normal human fetal astrocytes (healthy cells) at concentrations of up to 5 μM. As shown in Figure 3A, 19, 31, and 32 showed minimal toxicity at 5 μM, identifying a clear therapeutic window for these agents.

Next, to determine kinetic association and dissociation rate constants (k_{on} and k_{off}), surface plasmon resonance (SPR) binding experiments were performed using a ProteOn XPR36 (Biorad) with full length His-tagged STAT3 protein immobilized on the sensor chips. Promisingly, lead agents exhibited nanomolar binding potencies with 31, the most potent, exhibiting a K_{D} (k_{off}/k_{on}) of 300 ± 27 nM (Figure 3B). Thus, 31 represents a most potent, nonphosphorylated, small molecule STAT3 inhibitor. While phosphopeptides have been reported to bind to STAT3 with nanomolar potency, these agents have not shown in vivo efficacy. Comparative SPR analysis against STAT5, an analogous member of the STAT family proteins, showed modest selectivity (K_{D} = 464 ± 22 nM). Since the BTSCs evaluated do not harbor hyperactivated STAT5 (Supporting Information), we cannot attribute the observed activity to anti-STAT5 activity.

Next, to examine phosphopeptide:STAT3 SH2 domain disruption, compounds were subjected to a fluorescence polarization (FP) assay. As expected, prodrugs 15–16 and 19–24 displayed no disruptive potency. Inhibitors 31, 32, and 33 showed good inhibitory potency, disrupting STAT3:-phosphopeptide interactions with K_{D} ranging from 10 to 30 μM. Encouragingly, 33, 31, and 32 were selective for STAT3 over STAT1, a tumor suppressor protein (2-, 4-, and >10-fold selectivity for STAT3, respectively) (Supporting Information). Concerned that binding affinity was due to hydrophobic aggregation, we tested 30, which lacks the salicylic acid, and found that it had no binding affinity for the STAT3 protein (Supporting Information), thus confirming the requirement for the carboxylate for 31’s binding potency.

Next, to examine phosphopeptide:STAT3 SH2 domain disruption, compounds were subjected to a fluorescence polarization (FP) assay. As expected, prodrugs 15–16 and 19–24 displayed no disruptive potency. Inhibitors 31, 32, and 33 showed good inhibitory potency, disrupting STAT3:-phosphopeptide interactions with K_{D} ranging from 10 to 30 μM. Encouragingly, 33, 31, and 32 were selective for STAT3 over STAT1, a tumor suppressor protein (2-, 4-, and >10-fold selectivity for STAT3, respectively) (Supporting Information). Concerned that binding affinity was due to hydrophobic aggregation, we tested 30, which lacks the salicylic acid, and found that it had no binding affinity for the STAT3 protein (Supporting Information), thus confirming the requirement for the carboxylate for 31’s binding potency.

Next, to examine phosphopeptide:STAT3 SH2 domain disruption, compounds were subjected to a fluorescence polarization (FP) assay. As expected, prodrugs 15–16 and 19–24 displayed no disruptive potency. Inhibitors 31, 32, and 33 showed good inhibitory potency, disrupting STAT3:-phosphopeptide interactions with K_{D} ranging from 10 to 30 μM. Encouragingly, 33, 31, and 32 were selective for STAT3 over STAT1, a tumor suppressor protein (2-, 4-, and >10-fold selectivity for STAT3, respectively) (Supporting Information). Concerned that binding affinity was due to hydrophobic aggregation, we tested 30, which lacks the salicylic acid, and found that it had no binding affinity for the STAT3 protein (Supporting Information), thus confirming the requirement for the carboxylate for 31’s binding potency.

Next, to examine phosphopeptide:STAT3 SH2 domain disruption, compounds were subjected to a fluorescence polarization (FP) assay. As expected, prodrugs 15–16 and 19–24 displayed no disruptive potency. Inhibitors 31, 32, and 33 showed good inhibitory potency, disrupting STAT3:-phosphopeptide interactions with K_{D} ranging from 10 to 30 μM. Encouragingly, 33, 31, and 32 were selective for STAT3 over STAT1, a tumor suppressor protein (2-, 4-, and >10-fold selectivity for STAT3, respectively) (Supporting Information). Concerned that binding affinity was due to hydrophobic aggregation, we tested 30, which lacks the salicylic acid, and found that it had no binding affinity for the STAT3 protein (Supporting Information), thus confirming the requirement for the carboxylate for 31’s binding potency.

Next, to examine phosphopeptide:STAT3 SH2 domain disruption, compounds were subjected to a fluorescence polarization (FP) assay. As expected, prodrugs 15–16 and 19–24 displayed no disruptive potency. Inhibitors 31, 32, and 33 showed good inhibitory potency, disrupting STAT3:-phosphopeptide interactions with K_{D} ranging from 10 to 30 μM. Encouragingly, 33, 31, and 32 were selective for STAT3 over STAT1, a tumor suppressor protein (2-, 4-, and >10-fold selectivity for STAT3, respectively) (Supporting Information). Concerned that binding affinity was due to hydrophobic aggregation, we tested 30, which lacks the salicylic acid, and found that it had no binding affinity for the STAT3 protein (Supporting Information), thus confirming the requirement for the carboxylate for 31’s binding potency.
downstream targets involved in cell growth and survival (Cyclin D1 and Bcl-xl). Notably, 31 exhibited concentration-dependent decreases in pSTAT3 levels that correlated well with observed cytotoxicity and downstream target suppression. Treatment with 31 (500 nM) silenced pSTAT3 signaling in 147EF cells. Inhibitors 19 and 32, while less potent, exhibited negligible inhibition of pSTAT3.

To evaluate potential off-target effects, 19, 31, and 32 were screened in vitro for activity against cancer related kinases, c-Src, ERK1, Akt, JαK1, and JαK2 at 5 μM (Supporting Information). Inhibitors exhibited moderate to negligible activity against the kinases tested. Compounds showed negligible inhibition of Akt1, ERK1, and JαK1, while only exhibiting modest inhibition of JαK2, c-Src, and JαK2 (~50% inhibition at 5 μM). Since the concentration of inhibitor required to elicit effective kinase inhibition was 15-fold higher than the IC_{50} values in BTSCs, we concluded that activity was not a result of JαK kinase inhibition.

To comprehensively investigate potential off-target effects, 31 was subjected to a kinase screen (101 diverse kinases, DiscoveRx) as well as a protein and receptor screen (21 biologically important G protein-coupled receptors (GPCRs)). For kinase screening, ultrasensitive quantitative PCR (qPCR) was used to measure levels of immobilized kinases after treatment with 31. The GPCR screening employed the PathHunter β-arrestin assay platform (DiscoveRx) to evaluate 31. Encouragingly, 31 showed no off-target activity against any of the 21 GPCRs tested (500 nM). Moreover, in the kinase screen (500 nM), 31 showed negligible effects against SH2 (JαK1/2) and SH3 (Fes, Fgr, and Fyn) containing kinases with the exception of 35% inhibition of PDGFRB, a kinase implicated in glioblastoma. Concerned that 31 may act on PDGFRB to inhibit STAT3 activity, we conducted Western Blot analysis for activated PDGFRB in BTSCs as well as to determine the IC_{50} value of 31 against PDGFRB in vitro. Encouragingly, we found that PDGFRB activity was not present in any of the BTSCs examined (Supporting Information), and furthermore, as assessed by an enzymatic assay, 31 did not inhibit PDGFRB at concentrations of 10 μM (Supporting Information). Thus, to the best of our knowledge 31 directly inhibits STAT3.

Next, we compared 31 to a potent JαK2 inhibitor, WP1066, in 73M BTSCs (Figure 4C). Western blot analyses showed equipotent suppression of pSTAT3 at 1 μM. In a cytotoxicity assay, 31 was found to be more potent (30M, 31 IC_{50} = 0.43 μM, cf. WP1066 IC_{50} = 1.8 μM, and in 73M, 31 IC_{50} = 1.03 μM, cf. WP1066 IC_{50} = 2.1 μM (Supporting Information). Notably, 31 does not inhibit JαKs at therapeutic doses and appears to function through direct STAT3 inhibition. In addition, Western blot analysis of 31 vs 1, where comparative effects against pSTAT3 and pAkt were measured, as well as induced apoptosis as measured by cleaved PARP, demonstrated the superiority of 31 (Supporting Information).

To evaluate BBB penetration in vivo, 31 and 32 were given to three mice at 10 mg/kg and 25 mg/kg dosing (analogous to BP-1-102 in vivo dosing) via intraperitoneal injection, and blood was collected at two time points (30 and 300 min). Brain was also collected from one mouse at each dose and concentrations of 31 and 32 determined by LCMS. We found that after 30 min at 10 mg/kg, compound 31 was found at a concentration of 700 ± 140 nM (Supporting Information). Following these studies, three mice per group were dosed for five consecutive days with 10 mg/kg. Blood was collected at 30 and 300 min post the last dose, and brain was collected from all animals at the 300 min time-point. Then, 313 ± 8 nM of 31 was detected in the brains of treated animals (Supporting Information). Encouragingly, these studies demonstrated that therapeutic doses of 31 could be achieved in vivo at values similar to the in vitro IC_{50}s demonstrating efficacy against BTSCs.

Next, to evaluate 31 in vivo, NOD-SCID mice were orthotopically xenografted with 10^5 BT73 glioma cells. On the basis of the results for the above in vivo PK/PD and five-day maximum tolerated dose study, animals were dosed with 10 mg/kg, in order to achieve drug accumulation in the brains of the NOD-SCID mice at doses similar to in vitro IC_{50}s (Supporting Information). Therefore, starting on day 7, mice were given 10 doses of 10 mg/kg intraperitoneal injection of 31 or vehicle control on 4 days on/3 days off schedule. Animals were sacrificed 2 h after the last dose and brain tumors extracted and immunohistochemistry performed for pSTAT3, Ki67 (proliferation), and TUNEL (apoptosis). Analysis of tumors showed decreased tumor cells in 31 treated mice using Hematoxylin/Eosin staining (Figure 5A). Significantly, 31 decreased pSTAT3 expression in tumor cells of treated mice (Figure 5B). Furthermore, 31 appears to decrease proliferation (Figure 5C) and increase apoptosis (Figure 5D) of treated tumors showing decreased expression of proliferation marker Ki67 in mice treated with 31; (B) decreased pSTAT3 in mice orthotopically xenografted with BT73 and treated with 31; (C) increased expression of proliferation marker Ki67; (D) increased apoptosis (TUNEL staining) in mice treated with 31.

Figure 5. (A) Hematoxylin/Eosin staining: hypercellular tumor dense areas staining blue with hematoxylin. The images display brain tumor suppression for the mice treated with 31; (B) decreased pSTAT3 in mice orthotopically xenografted with BT73 and treated with 31; (C) decreased expression of proliferation marker Ki67 in mice treated with 31; (D) increased apoptosis (TUNEL staining) in mice treated with 31.
tumors. Thus, in vivo studies strongly suggest in vivo potency and on-target anti-STAT3 activity.

In summary, to the best of our knowledge, we have identified a most potent, nonphosphorylated direct binding STAT3 inhibitor, 31 (SH-4-54). Compound 31 exhibited nanomolar K_D values for STAT3, showed unprecedented cytotoxicity in human BTSCs, displayed no toxicity in human fetal astrocytes, potently suppressed pSTAT3 with nanomolar IC_50s, inhibited STAT3's downstream targets, and showed no discernible off-target effects at therapeutic doses. Moreover, in vivo, 31 exhibits BBB permeability, potently suppresses glioma tumor growth, and inhibits pSTAT3 in vivo. This work, for the first time, demonstrates the power of STAT3 inhibitors for the treatment of BTSCs and validates the therapeutic efficacy of a STAT3 inhibitor for GBM clinical application.

**ASSOCIATED CONTENT**

2 Supporting Information

Information on synthesis, characterization, detailed results, and experimental procedures for SPR, Cytotoxicity, BBB permeability, and in vivo assays. This material is available free of charge via the Internet at http://pubs.acs.org.

**AUTHOR INFORMATION**

Corresponding Authors
*(P.T.G.) E-mail: patrick.gunning@utoronto.ca,*
*(S.W.) E-mail: weiss@ucalgary.ca.*

Author Contributions
*S.H. and H.A.L. contributed equally to this work.

Funding

Financial support was provided by Boehringer Ingelheim Canada (to P.T.G.), Stem Cell Network (to S.W. and P.T.G.), NSERC Discovery Grant (to P.T.G. and K.K.), NSERC Graduate Scholarship (S.H. and B.D.G.P.), and Ontario Graduate Scholarship (to V.M.S.).

Notes

The authors declare no competing financial interest.

**REFERENCES**


(21) Kelly, J. J.; Stechishin, O.; Chojnacki, A.; Lun, X.; Sun, B.; Senger, D. L.; Forsyth, P.; Auer, R. N.; Dunn, J. F.; Cairncross, J. G.;


